AMENDMENTS TO THE CLAIMS:

Please cancel claims 1-60 and 62-66 without prejudice.

Please add new claims 67-84.

Please amend claim 61 as follows:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-60 (**Cancelled**)

61. (**Currently amended**) A method for diagnosing cancer comprising :
~~a) determining the~~ detecting evidence of differential expression of CR1 in a patient sample, ~~one or more genes comprising a nucleic acid sequence selected from the group consisting of the human genomic and mRNA sequences outlined in Tables 1-124, in a first tissue type of a first individual; and~~
~~b) comparing said expression of said gene(s) from a second normal tissue type from said first individual or a second unaffected individual;~~
wherein ~~a difference in said~~ evidence of differential expression of CR1 indicates that the ~~first individual~~ patient has cancer.

Claims 62-66 (**Cancelled**)

67. (New) The method of claim 61, wherein the difference in said expression indicates that the patient has a propensity towards cancer.

68. (New) The method of claim 61 wherein the cancer is selected from the group consisting of lymphoma, leukemia, carcinoma, breast cancer and colon cancer.

69. (New) The method of claim 61, wherein CR1 gene expression in the patient sample is up-

regulated relative to CR1 gene expression in normal tissue.

70. (New) The method of claim 69, wherein up-regulation of expression indicates that the patient has a propensity towards cancer.

71. (New) The method of claim 61 wherein evidence of differential expression is detected by measuring the level of an expression product of CR1.

72. (New) The method of claim 71 wherein the expression product is a polypeptide or mRNA.

73. (New) The method of claim 71 wherein the expression product is a mRNA having a sequence at least 98% identical to SEQ ID NO:1320, or a complement thereof.

74. (New) The method of claim 71 wherein the expression product is a mRNA having a sequence of SEQ ID NO:1320, or a complement thereof.

75. (New) The method of claim 71 wherein the level of expression product in the patient sample is compared to a control.

76. (New) The method of claim 75 wherein the control is a known normal tissue of the same tissue type as in the patient sample.

77. (New) The method of claim 75 wherein the level of the expression product in the sample is increased at least 50% relative to the control.

78. (New) The method of claim 75 wherein the level of the expression product in the sample is increased at least 100% relative to the control.

79. (New) The method of claim 75 wherein the level of the expression product in the sample is increased at least 150% relative to the control.

80. (New) The method of claim 61, wherein the patient sample comprises tissue selected from the group consisting of lymphatic tissue, breast tissue and colon tissue.

81. (New) A method of diagnosing cancer comprising:

a) determining the level of an expression product comprising a nucleotide sequence having at least 95% sequence identity to a sequence of SEQ ID NO:1320, or a complement thereof, in a patient sample; and

b) comparing said level of the expression product in (a) to a level of the expression product in a second sample, said second sample comprising a normal tissue, wherein a difference between the level of the expression products in (a) and the level of the expression products in the second sample indicates that the patient has lymphoma, leukemia, carcinoma, breast cancer or colon cancer

82. (New) A method of screening for anti-cancer activity comprising:

(a) contacting a cell that expresses a gene with a candidate anti-cancer agent, said gene comprising a nucleotide sequence at least 95% identical to SEQ ID NO:1320, or a complement thereof; and

(b) detecting a difference between the level of gene expression in the cell in the presence and in the absence of the candidate anti-cancer agent, wherein a difference between the level of gene expression in the cell in the presence and in the absence of the candidate anti-cancer agent indicates that the candidate anti-cancer agent has anti-cancer activity.

83. (New) The method of claim 82 wherein the candidate anti-cancer agent is an antibody, small organic compound, small inorganic compound or polynucleotide.

84. (New) The method of claim 82 wherein the cancer is lymphoma, leukemia, carcinoma, breast cancer or colon cancer